Zevra Therapeutics (ZVRA) Prepaid Assets (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Prepaid Assets came in at $4.9 million in Q1 2026, up 31.28% YoY from $3.8 million in Q1 2025, and down 29.35% on a QoQ basis from $7.0 million in Q4 2025.
Analysis
Zevra Therapeutics (ZVRA) Prepaid Assets (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Prepaid Assets data on file, last reported at $4.9 million in Q1 2026.
- Quarterly Prepaid Assets rose 31.28% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 31.28% YoY) and the FY2025 annual result came in at $7.0 million, up 72.7% from the prior year.
- Prepaid Assets slipped to $4.9 million in Q1 2026, from $7.0 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $7.4 million in Q3 2025 to a low of -$426000.0 in Q2 2022.
- A 5-year average of $2.8 million and a median of $2.3 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets plunged 128.25% — and 2023, when it surged 489.91%.
- Tracing ZVRA's Prepaid Assets over 5 years: stood at $1.7 million in 2022, then tumbled by 30.57% to $1.2 million in 2023, then jumped by 245.73% to $4.1 million in 2024, then soared by 72.7% to $7.0 million in 2025, then decreased by 29.35% to $4.9 million in 2026.
- The last three Prepaid Assets figures came in at $4.9 million (Q1 2026), $7.0 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.79 Mn |
| Mar 31, 2026 | 4.94 Mn |
| Dec 31, 2025 | 7.00 Mn |
| Sep 30, 2025 | 7.40 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Mar 31, 2025 | 3.77 Mn |
| Dec 31, 2024 | 4.05 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 2.69 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Dec 31, 2023 | 1.82 Mn |
| Sep 30, 2023 | 1.66 Mn |
| Jun 30, 2023 | 2.02 Mn |
| Mar 31, 2023 | 1.17 Mn |
| Dec 31, 2022 | 1.69 Mn |
| Sep 30, 2022 | 2.66 Mn |
| Jun 30, 2022 | 3.64 Mn |
| Mar 31, 2022 | 880,000.00 |
| Dec 31, 2021 | 1.18 Mn |
| Sep 30, 2021 | 1.51 Mn |